Medivation (MDVN) : Fridays money flow analysis of Medivation (MDVN) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $81.68 million. In comparison, the inflow of money on upticks was a meager $40.06 million. The dollar value of composite uptick trades minus the downtick trades was negative $41.62 million. The uptick to downtick ratio of 0.49 in the money flow shows weakness. The uptick block trades were valued at $2.81 million. The downtick transaction value was high at $43.77 million, which denotes distribution on strength. The uptick to downtick ratio of block trades was 0.06. Hence, the net money flow in the stock was negative ($40.95 million). Medivation (MDVN) gained $0.37 at $80.93, a change of 0.46% over the previous days close.
The company Insiders own 3.54% of Medivation shares according to the proxy statements. Institutional Investors own 88.59% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of -18.41%.
In a related news, The Securities and Exchange Commission has divulged that Powell Andrew Kenneth William, officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., had unloaded 2,578 shares at an average price of $60.42 in a transaction dated on June 6, 2016. The total value of the transaction was worth $155,763.
Medivation (NASDAQ:MDVN): stock was range-bound between the intraday low of $80.72 and the intraday high of $80.98 after having opened at $80.91 on Fridays session. The stock finally closed in the red at $80.91, a loss of -0.10%. The stock remained in the red for the whole trading day. The total traded volume was 3,300,390 shares. The stock failed to cross $80.98 in Fridays trading. The stocks closing price on Thursday was $80.93.
Medivation (MDVN) : Traders are bullish on Medivation (MDVN) as it has outperformed the S&P 500 by a wide margin of 28% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.12%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.62% in the last 1 week, and is up 27.83% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.